In this study, the effects of first-line therapy for newly diagnosed ATL and PTCL patients on NK cells defined as CD16/CD56 double-positive ones can cause high ADCC for defucosylated antibodies such as mogamulizumab were evaluated using NK cell number and NK cell activity substitute functional cell vitality as indices. This evidence concerns the gene NCAM1 and mature T-cell and NK-cell non-Hodgkin lymphoma.